Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25465739 | 1.00 | HPGD (0.46) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL16044435 | 0.90 | HPGD (0.41) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL16042190 | 0.87 | HPGD (0.46) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL16042188 | 0.87 | HPGD (0.46) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL16463653 | 0.87 | RECQL (0.47) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL16042332 | 0.87 | HPGD (0.46) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL29699144 | 0.84 | HPGD (0.41) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL21748741 | 0.84 | NR1H2 (0.42) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL30595257 | 0.84 | NR1H2 (0.42) | HPGDRECQLEPHX1KDM1AKDM4E | |
| SCHEMBL24231705 | 0.84 | NR1H2 (0.42) | HPGDRECQLEPHX1KDM1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2025-07-03 | — | — | US | disclosed |
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-12 | — | — | US | disclosed |
| WO-2025092695-A1 | NEW HETEROCYCLIC COVALENT INHIBITOR OF MENIN, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | 成都苑东生物制药股份有限公司 | 2025-05-08 | — | — | WO | disclosed |
| CN-119585238-A | N- (pyrrolidin-3-yl or piperidin-4-yl) acetamide derivatives | 武田药品工业株式会社 | 2025-03-07 | — | — | CN | disclosed |
| EP-4514793-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2025-03-05 | — | — | EP | disclosed |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-02-13 | — | — | US | disclosed |
| EP-4499224-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2025-02-05 | — | — | EP | disclosed |
| CN-119156385-A | Fused bicyclic heteroaromatic compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-12-17 | — | — | CN | disclosed |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-11 | — | — | US | disclosed |
| CN-112236423-B | Piperidinyl-3- (aryloxy) propanamides and propionic acid esters | 武田药品工业株式会社 | 2024-02-06 | — | — | CN | disclosed |
| WO-2023209084-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023209090-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023187677-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-05 | — | — | WO | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-06-29 | — | — | US | disclosed |
| EP-3759094-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | Takeda Pharmaceutical Company Limited (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-27 | — | — | US | disclosed |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | SSTR4, SSTR3, SSTR1 | HPGD 3435/4885RECQL 1498/4885EPHX1 3940/4885 |
| US-11045457-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | HPGD 2783/4885RECQL 2139/4885EPHX1 2969/4885 |
| US-12005054-B2 | Piperidinyl-3-(aryloxy)propanamides and propanoates | SSTR4, SSTR3, NPY4R | HPGD 2783/4885RECQL 2139/4885EPHX1 2969/4885 |
| US-20250049772-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | HPGD 2783/4885RECQL 2139/4885EPHX1 2969/4885 |
| US-20200061041-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | HPGD 2783/4885RECQL 2139/4885EPHX1 2969/4885 |
| US-20250214995-A1 | CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, TP53, SDHA | HPGD 453/4885RECQL 394/4885EPHX1 1980/4885 |
| US-20230021834-A1 | PIPERIDINYL-3-(ARYLOXY)PROPANAMIDES AND PROPANOATES | SSTR4, SSTR3, NPY4R | HPGD 2783/4885RECQL 2139/4885EPHX1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.